CureVac and WACKER sign contract to manufacture COVID-19 vaccine candidate

WACKER Chemie has signed a contract with biopharmaceutical company, CureVac, for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV.

Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021. Preparations for the start of production, technology transfers and test runs are already underway. It is planned to produce more than 100 million doses of the CureVac vaccine per year at WACKER’s Amsterdam site. There is also further potential for expansion at the site in order to meet rising demand in the future.

COVID-19 Image by Gerd Altmann from Pixabay
CureVac began development of its mRNA-based COVID-19 vaccine candidate in January 2020

Fight against COVID-19

WACKER’s CEO Rudolf Staudigl says: “We are proud and highly motivated to make a contribution to the fight against the spread of the coronavirus pandemic together with CureVac.” As a CDMO (Contract Development and Manufacturing Organisation), Wacker Biotech bundles WACKER Group’s biopharmaceutical activities. Its Amsterdam site has been producing vaccines for clinical development and commercial supply for 20 years. The portfolio ranges from conventional live and killed vaccines to protein-based, polysaccharide and glycoconjugate vaccines. In recent months, WACKER has invested in the site to extend production to include mRNA-based vaccines. This new class of vaccines expands the broad vaccine portfolio Wacker Biotech offers to its customers.

Dr Florian von der Mülbe, chief production officer of CureVac, adds: “With WACKER, we have found a committed and highly experienced partner for the production of our vaccine candidate in the Netherlands.” CureVac is building an integrated European vaccine manufacturing network with several CDMO partners. With this strategy, the company will significantly increase the manufacturing capacity already existing within CureVac for CVnCoV up to several hundred million doses per year and will manage potential supply chain risks by working with several partners for each of the key manufacturing process steps.

CVnCoV

CureVac began development of its mRNA-based COVID-19 vaccine candidate in January 2020. The compound is an optimised, non- chemically modified mRNA, encoding the prefusion stabilised full-length spike protein of the SARS-CoV-2 virus. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody responses in addition to first indication of T cell activation. The quality of immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection. The data support CureVac’s decision to advance a 12μg dose in its upcoming pivotal Phase 2b/3 study, which CureVac plans to initiate before the end of 2020.

Clinical trial material is provided by the company’s substantial production capacities for mRNA vaccines at its headquarters in Tübingen, supported by the current expansion of manufacturing capacities to allow for broad-scale manufacturing of CVnCoV for potential commercial supply preparedness.



Latest


22 Jan 2021
Clere celebrates 60 years of spreading the love for skin

This year heritage skin care brand, Clere is celebrating its 60th anniversary. “The name Clere has been synonymous with soft,…

Clere celebrates 60 years of spreading the love for skin

This year heritage skin care brand, Clere is celebrating its 60th anniversary. “The name Clere has been synonymous with soft, smooth, beautiful looking skin for six decades now. It’s a favourite in both South African homes and those abroad. Over the years Clere has managed to remain relevant, and up…

21 Jan 2021
COVID-19 vaccine – how will Africa keep it cold enough?

While we await the first vaccines to either arrive in the country via air, or under licence from local manufactured…

COVID-19 vaccine – how will Africa keep it cold enough?

While we await the first vaccines to either arrive in the country via air, or under licence from local manufactured sources, there remains another obstacle. The so-called cold supply chain that needs to remain intact when delivering the COVID-19 vaccine to all corners of the country. The temperatures needed for…

18 Jan 2021
Solvay commits to sustainable cyclopentanone production

Solvay has begun a process of decarbonising the cyclopentanone unit of its Melle plant in France. Through an agreement with…

Solvay commits to sustainable cyclopentanone production

Solvay has begun a process of decarbonising the cyclopentanone unit of its Melle plant in France. Through an agreement with an agricultural cooperative for the next 15 years, the entire cyclopentanone production will indeed rely solely on biomethane gas, a green source of energy. The cooperative built a facility to…

18 Jan 2021
Irene Cantos becomes IMCD’s group director Personal Care

IMCD has appointed Irene Cantos as business group director Personal Care, effective 6 January 2021. In her role, Cantos, will…

Irene Cantos becomes IMCD’s group director Personal Care

IMCD has appointed Irene Cantos as business group director Personal Care, effective 6 January 2021. In her role, Cantos, will lead the Business Group Personal Care in becoming the global player of choice for both suppliers and customers in the distribution of speciality ingredients. The group aims to grow both…


Top stories


25 Jun 2020
How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a…

How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a changing environment, whether it be internal or external. Qualities of agile businesses include being adaptive, flexible and creative in your response to change without losing momentum (remaining productive) or vision.…

01 May 2020
Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex,…

Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex, which continuously invests in technological advancements to meet requirements in diverse industries – has increased production capacity of materials so desperately needed during the global COVID-19 pandemic,” explains Rosa Naidoo,…

23 Apr 2020
Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love.…

Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love. Santam, Fairlady and, for the first time this year, Truelove Magazine, have partnered up in the search to find the best female entrepreneurs in the country. Best women entrepreneurs If…

30 Nov 2017
Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form…

Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form of diabetes, known as “type 3” diabetes and Alzheimer’s disease.


Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za